Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting

tors and interferons, and discovering important insights into possible treatment regimens for chronic hepatitis C," said Lawrence M. Blatt, Ph.D., Chief Scientific Officer of InterMune. "We anticipate that treatment regimens will involve multiple agents, and we are hopeful that these combinations will lead to improved, sustained virologic responses for patients who are in need of more optimal therapies."

The third presentation concerned NS3 sequence variations in HCV replicons after exposure to ITMN-191 at clinically relevant concentrations. The NS3 sequence was found to undergo dynamic changes when exposed to increasing concentrations of ITMN-191. As was seen in previous work, substitution at position 168 of NS3 appears to be fundamental to resistance but alone is not sufficient for HCV replicon persistence at all ITMN-191 concentrations achieved in the liver of animal species following oral dosing. This suggests that the genetic barrier to resistance in patients following clinical dosing of ITMN-191 may be significant dependent upon human liver exposure.

InterMune currently is conducting a Phase 1a clinical study of ITMN-191 for the treatment of chronic HCV. Preclinical toxicology and pharmacokinetic studies in multiple species demonstrated that ITMN-191 has a favorable toxicology profile, significant liver exposure, high in vitro potency and specificity, and an advantageous cross-resistance profile, including considerable effectiveness against variants of the NS3/4A protease that are resistant to other HCV protease inhibitors currently in development. The preclinical pharmacokinetic results support the exploration of twice-daily oral dosing. InterMune and Roche have a collaboration agreement for the research, development and commercialization of ITMN-191 (referred to as R7227 within the Roche research and development programs) and second-generation HCV protease inhibitor compounds.

According to the Centers for Disease Control and Prevention (
'"/>




Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: InterMune Presents Research ITMN Hepatitis EASL Annual Meeting
(Date:9/18/2014)... 2014 Just days before the government of ... contain the spread of Ebola, World Vision will begin a ... thanks to private donations. McKesson, the largest healthcare ... through its affiliate McKesson Medical-Surgical donated four million pairs of ... Sierra Leone,s needs for the next ...
(Date:9/18/2014)... MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa. ... (Nasdaq: VVUS ) and Auxilium Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has approved a ... STENDRA is now the only FDA-approved erectile dysfunction (ED) medication ... before sexual activity. STENDRA is a prescription medication ...
(Date:9/17/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Market Research Report ... Market Research Report on Global and China Isothiocyanate ... Photo - http://photos.prnewswire.com/prnh/20140917/146748 ... Methacrylate (MMA) Industry" is a professional and in-depth ... and Global Methyl Methacrylate (MMA) market. The report ...
Breaking Medicine Technology:World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 2Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 3Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 4Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 5
(Date:9/18/2014)... (PRWEB) September 18, 2014 Technology Association ... winners of its 2nd TAG Social Savvy Awards this ... Achievement’s Chick-fil-A Foundation Discovery Center in Downtown Atlanta. The ... , Turner Sports was honored with the 2014 ... year’s event also recognized innovators in 6 other award ...
(Date:9/18/2014)... A sold-out crowd of more than ... supported United Way of Westchester and Putnam ... event Monday, Sept. 15. Proceeds from the event will ... and Putnam, such as providing healthy foods to low-income ... risky behaviors like drug and alcohol usage. , Two ...
(Date:9/18/2014)... -- Teens and young adults who,ve been mentored may ... them with greater responsibility and independence early on in ... found that having a mentor provides a clear benefit ... Steve McDonald, an associate professor of sociology at North ... In conducting the study, published online recently ...
(Date:9/18/2014)... A common Asian spice and cancer-hampering molecules show ... cancer of the lung,s lining often linked to ... the Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application ... and cancer-inhibiting peptides increase levels of a protein ... cancer. Their findings appeared in the Aug. 14 ...
(Date:9/18/2014)... Research led by Paulo Rodriguez, PhD, an assistant research ... New Orleans, Stanley S. Scott Cancer Center, has identified ... plays in the body,s ability to fight cancer. Results ... activity and accumulation of cells that suppress the body,s ... research team showed that when they removed Chop, the ...
Breaking Medicine News(10 mins):Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3Health News: Mentors May Steer Young People Toward More Rewarding Careers 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 3Health News:LSU Health research discovers means to free immune system to destroy cancer 2
... July 30 On Wednesday, July 30th,Representative Jose ... Act, a bill which, if passed, will remove ... spend federal funding that,they receive for prevention of ... method of HIV prevention which helps intravenous,drug users ...
... Company,s Fourth FDA 510(k) Clearance Since December 2007, ... Corp.,(Nasdaq: ESMC ) today announced that the ... the 510(k) submission for the LIASYS(TM),bench top clinical ... Diagnostic ("JAS") unit is the distributor,for the LIASYS ...
... CYT, MONTREAL, July 30 /PRNewswire-FirstCall/ - CryoCath ... products to treat cardiac,arrhythmias, today announced that Jan ... corporate update at the BMO Focus on Healthcare,Conference. ... at 8:30 a.m. (ET) in Room 2 at ...
... of Dr. Julius,Richmond, one of the founding fathers ... Americans who care about childhood education, health and ... (NHSA), the organization,representing children, family, educators and others ... education program., A statement issued today by ...
... travel to China for the 2008 Olympic Games, travelers ... bites, according to report by an Emory University travelers, ... Control and Prevention (CDC) and around the globe. ... rabies. The report finds that respiratory illnesses and dog ...
... American Association of Pharmaceutical Scientists (AAPS) will co-sponsor Immunogenicity ... , ... Horsham, PA ... (DIA) and the American Association of Pharmaceutical Scientists (AAPS) ...
Cached Medicine News:Health News:AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs 2Health News:AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs 3Health News:AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs 4Health News:AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs 5Health News:AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs 6Health News:AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs 7Health News:AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs 8Health News:AIDS Action Applauds Introduction of a New Bill Allowing Federal Funds to Support Syringe Exchange Programs 9Health News:Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer 2Health News:Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer 3Health News:NHSA: Head Start Community Mourns Passing of Pioneer Dr. Julius Richmond 2Health News:Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics 2Health News:DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins 2
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
... High performance plus simple ... gentle and efficient washing ... is performed with minimum ... cells while membrane bound ...
Stat Fax 2600 is fully automatic microplate washer....
The Microtech Microplate Washer (220 V) is a flexible and ultra compact microplate washer. The system offers a wide choice of washing functions and sequences designed to handle most any microplate ap...
Medicine Products: